^
    Back
    Association details:
    Biomarker:IKZF1 deletion + PAX5 deletion
    Cancer:Acute Lymphocytic Leukemia
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) +
    Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    N Engl J Med
    Title:

    Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults

    Published date:
    10/22/2020
    Excerpt:
    At a median follow-up of 18 months, overall survival was 95% and disease-free survival was 88%; disease-free survival was lower among patients who had an IKZF1 deletion plus additional genetic aberrations (CDKN2A or CDKN2B, PAX5, or both [i.e., IKZF1plus])....first-line treatment with dasatinib and blinatumomab...
    DOI:
    10.1056/NEJMoa2016272
    Trial ID:
    2016-001083-11; GIMEMA LAL2116